المؤلفون: Mottola, Clément, Girerd, Nicolas, Duarte, Kévin, Aarnink, Alice, Giral, Magali, Dantal, Jacques, Garrigue, Valérie, Mourad, Georges, Buron, Fanny, Morélon, Emmanuel, Ladrière, Marc, Kessler, Michèle, Frimat, Luc, Girerd, Sophie

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire d'immunologie et d'histocompatibilité, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), RTRS « Centaure », Service de Néphrologie, Dialyse et Transplantation (Hôpital Lapeyronie Montpellier CHU), Hôpital Lapeyronie Montpellier (CHU), Service de Transplantation, Néphrologie et Immunologie Clinique Hôpital Edouard Herriot, HCL, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: ischaemia reperfusion injury, graft survival, kidney transplantation, creatinine, delayed graft function, proteinuria, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

الوصف: International audience ; Background. The estimated glomerular filtration rate (eGFR) measured at 1 year is the usual benchmark applied in kidneytransplantation (KT). However, acting on earlier eGFR values could help in managing KT during the first post-operative year.We aimed to assess the prognostic value for long-termgraft survival of the early (3 months) quantification of eGFR andproteinuria following KT.Methods. The 3-, 6- and 12-month eGFR using the Modified Diet in Renal Disease equation (eGFRMDRD) was determined andproteinuria was measured in 754 patients who underwent their first KT between 2000 and 2010 (with a mean follow-up of8.3 years) in our centre. Adjusted associations with graft survival were estimated using a multivariable Cox model. Thepredictive accuracy was estimated using the C-index and net reclassification index. These same analyses were measured ina multicentre validation cohort of 1936 patients.Results. Both 3-month eGFRMDRD and proteinuria were independent predictors of return to dialysis (all P<0.05) and therewas a strong correlation between eGFR at 3 and 12 months (Spearman’s q¼0.76). The predictive accuracy of the 3-month

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33125000; hal-02880287; https://hal.univ-lorraine.fr/hal-02880287Test; https://hal.univ-lorraine.fr/hal-02880287/documentTest; https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest; PUBMED: 33125000; PUBMEDCENTRAL: PMC7577768

الإتاحة: https://doi.org/10.1093/ckj/sfaa044Test
https://doi.org/10.1093/ckj/sfaa044/5825430Test
https://hal.univ-lorraine.fr/hal-02880287Test
https://hal.univ-lorraine.fr/hal-02880287/documentTest
https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest

المؤلفون: Mottola, Clément, Girerd, Nicolas, Duarte, Kévin, Aarnink, Alice, Giral, Magali, Dantal, Jacques, Garrigue, Valérie, Mourad, Georges, Buron, Fanny, Morélon, Emmanuel, Ladrière, Marc, Kessler, Michèle, Frimat, Luc, Girerd, Sophie

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire d'immunologie et d'histocompatibilité, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), RTRS « Centaure », Service de Néphrologie, Dialyse et Transplantation (Hôpital Lapeyronie Montpellier CHU), Hôpital Lapeyronie Montpellier (CHU), Service de Transplantation, Néphrologie et Immunologie Clinique Hôpital Edouard Herriot, HCL, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: ischaemia reperfusion injury, graft survival, kidney transplantation, creatinine, delayed graft function, proteinuria, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

الوصف: International audience ; Background. The estimated glomerular filtration rate (eGFR) measured at 1 year is the usual benchmark applied in kidneytransplantation (KT). However, acting on earlier eGFR values could help in managing KT during the first post-operative year.We aimed to assess the prognostic value for long-termgraft survival of the early (3 months) quantification of eGFR andproteinuria following KT.Methods. The 3-, 6- and 12-month eGFR using the Modified Diet in Renal Disease equation (eGFRMDRD) was determined andproteinuria was measured in 754 patients who underwent their first KT between 2000 and 2010 (with a mean follow-up of8.3 years) in our centre. Adjusted associations with graft survival were estimated using a multivariable Cox model. Thepredictive accuracy was estimated using the C-index and net reclassification index. These same analyses were measured ina multicentre validation cohort of 1936 patients.Results. Both 3-month eGFRMDRD and proteinuria were independent predictors of return to dialysis (all P<0.05) and therewas a strong correlation between eGFR at 3 and 12 months (Spearman’s q¼0.76). The predictive accuracy of the 3-month

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33125000; hal-02880287; https://hal.univ-lorraine.fr/hal-02880287Test; https://hal.univ-lorraine.fr/hal-02880287/documentTest; https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest; PUBMED: 33125000; PUBMEDCENTRAL: PMC7577768

الإتاحة: https://doi.org/10.1093/ckj/sfaa044Test
https://doi.org/10.1093/ckj/sfaa044/5825430Test
https://hal.univ-lorraine.fr/hal-02880287Test
https://hal.univ-lorraine.fr/hal-02880287/documentTest
https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest

المؤلفون: Girerd, Sophie, Girerd, Nicolas, Frimat, Luc, Holdaas, Hallvard, Jardine, Alan, G, Schmieder, Roland, E, Fellström, Bengt, Settembre, Nicla, Malikov, Sergei, Rossignol, Patrick, Zannad, Faiez

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), University of Oslo (UiO), Renal Research Group, British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), University of Glasgow-NHS Greater Glasgow & Clyde Glasgow (NHSGGC), Department of Nephrology and Hypertension, University Hospital Erlangen, Department of Nephrology, University Hospital, Uppsala, Service de Chirurgie Cardio-vasculaire CHRU Nancy, P.R., N.G. and F.Z. are supported by a public grant overseen by the French National Research Agency (ANR) as part of the second Investissements d’Avenir’ programme (reference ANR-15-RHU-0004). The subjects have given their written informed consent. The study protocol has been approved by the research institute’s committee on human research., ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: survival, vascular access complication, chronic haemodialysis, cardiovascular mortality, arteriovenous fistula, arteriovenous graft, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.Methods: The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome.Results: During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001].Conclusions: AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32082562; hal-02571720; https://hal.univ-lorraine.fr/hal-02571720Test; https://hal.univ-lorraine.fr/hal-02571720/documentTest; https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest; PUBMED: 32082562; PUBMEDCENTRAL: PMC7025348

الإتاحة: https://doi.org/10.1093/ckj/sfz048Test
https://hal.univ-lorraine.fr/hal-02571720Test
https://hal.univ-lorraine.fr/hal-02571720/documentTest
https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest

المؤلفون: Mottola, Clément, Girerd, Nicolas, Duarte, Kévin, Aarnink, Alice, Giral, Magali, Dantal, Jacques, Garrigue, Valérie, Mourad, Georges, Buron, Fanny, Morélon, Emmanuel, Ladrière, Marc, Kessler, Michèle, Frimat, Luc, Girerd, Sophie

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire d'immunologie et d'histocompatibilité, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), RTRS « Centaure », Service de Néphrologie, Dialyse et Transplantation (Hôpital Lapeyronie Montpellier CHU), Hôpital Lapeyronie Montpellier (CHU), Service de Transplantation, Néphrologie et Immunologie Clinique Hôpital Edouard Herriot, HCL, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: ischaemia reperfusion injury, graft survival, kidney transplantation, creatinine, delayed graft function, proteinuria, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

الوصف: International audience ; Background. The estimated glomerular filtration rate (eGFR) measured at 1 year is the usual benchmark applied in kidneytransplantation (KT). However, acting on earlier eGFR values could help in managing KT during the first post-operative year.We aimed to assess the prognostic value for long-termgraft survival of the early (3 months) quantification of eGFR andproteinuria following KT.Methods. The 3-, 6- and 12-month eGFR using the Modified Diet in Renal Disease equation (eGFRMDRD) was determined andproteinuria was measured in 754 patients who underwent their first KT between 2000 and 2010 (with a mean follow-up of8.3 years) in our centre. Adjusted associations with graft survival were estimated using a multivariable Cox model. Thepredictive accuracy was estimated using the C-index and net reclassification index. These same analyses were measured ina multicentre validation cohort of 1936 patients.Results. Both 3-month eGFRMDRD and proteinuria were independent predictors of return to dialysis (all P<0.05) and therewas a strong correlation between eGFR at 3 and 12 months (Spearman’s q¼0.76). The predictive accuracy of the 3-month

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33125000; hal-02880287; https://hal.univ-lorraine.fr/hal-02880287Test; https://hal.univ-lorraine.fr/hal-02880287/documentTest; https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest; PUBMED: 33125000; PUBMEDCENTRAL: PMC7577768

الإتاحة: https://doi.org/10.1093/ckj/sfaa044Test
https://doi.org/10.1093/ckj/sfaa044/5825430Test
https://hal.univ-lorraine.fr/hal-02880287Test
https://hal.univ-lorraine.fr/hal-02880287/documentTest
https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest

المؤلفون: Girerd, Sophie, Girerd, Nicolas, Frimat, Luc, Holdaas, Hallvard, Jardine, Alan, G, Schmieder, Roland, E, Fellström, Bengt, Settembre, Nicla, Malikov, Sergei, Rossignol, Patrick, Zannad, Faiez

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), University of Oslo (UiO), Renal Research Group, British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), University of Glasgow-NHS Greater Glasgow & Clyde Glasgow (NHSGGC), Department of Nephrology and Hypertension, University Hospital Erlangen, Department of Nephrology, University Hospital, Uppsala, Service de Chirurgie Cardio-vasculaire CHRU Nancy, P.R., N.G. and F.Z. are supported by a public grant overseen by the French National Research Agency (ANR) as part of the second Investissements d’Avenir’ programme (reference ANR-15-RHU-0004). The subjects have given their written informed consent. The study protocol has been approved by the research institute’s committee on human research., ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: survival, vascular access complication, chronic haemodialysis, cardiovascular mortality, arteriovenous fistula, arteriovenous graft, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.Methods: The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome.Results: During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001].Conclusions: AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32082562; hal-02571720; https://hal.univ-lorraine.fr/hal-02571720Test; https://hal.univ-lorraine.fr/hal-02571720/documentTest; https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest; PUBMED: 32082562; PUBMEDCENTRAL: PMC7025348

الإتاحة: https://doi.org/10.1093/ckj/sfz048Test
https://hal.univ-lorraine.fr/hal-02571720Test
https://hal.univ-lorraine.fr/hal-02571720/documentTest
https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest

المؤلفون: Mottola, Clément, Girerd, Nicolas, Duarte, Kévin, Aarnink, Alice, Giral, Magali, Dantal, Jacques, Garrigue, Valérie, Mourad, Georges, Buron, Fanny, Morélon, Emmanuel, Ladrière, Marc, Kessler, Michèle, Frimat, Luc, Girerd, Sophie

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire d'immunologie et d'histocompatibilité, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), RTRS « Centaure », Service de Néphrologie, Dialyse et Transplantation (Hôpital Lapeyronie Montpellier CHU), Hôpital Lapeyronie Montpellier (CHU), Service de Transplantation, Néphrologie et Immunologie Clinique Hôpital Edouard Herriot, HCL, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: ischaemia reperfusion injury, graft survival, kidney transplantation, creatinine, delayed graft function, proteinuria, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

الوصف: International audience ; Background. The estimated glomerular filtration rate (eGFR) measured at 1 year is the usual benchmark applied in kidneytransplantation (KT). However, acting on earlier eGFR values could help in managing KT during the first post-operative year.We aimed to assess the prognostic value for long-termgraft survival of the early (3 months) quantification of eGFR andproteinuria following KT.Methods. The 3-, 6- and 12-month eGFR using the Modified Diet in Renal Disease equation (eGFRMDRD) was determined andproteinuria was measured in 754 patients who underwent their first KT between 2000 and 2010 (with a mean follow-up of8.3 years) in our centre. Adjusted associations with graft survival were estimated using a multivariable Cox model. Thepredictive accuracy was estimated using the C-index and net reclassification index. These same analyses were measured ina multicentre validation cohort of 1936 patients.Results. Both 3-month eGFRMDRD and proteinuria were independent predictors of return to dialysis (all P<0.05) and therewas a strong correlation between eGFR at 3 and 12 months (Spearman’s q¼0.76). The predictive accuracy of the 3-month

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33125000; hal-02880287; https://hal.univ-lorraine.fr/hal-02880287Test; https://hal.univ-lorraine.fr/hal-02880287/documentTest; https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest; PUBMED: 33125000; PUBMEDCENTRAL: PMC7577768

الإتاحة: https://doi.org/10.1093/ckj/sfaa044Test
https://doi.org/10.1093/ckj/sfaa044/5825430Test
https://hal.univ-lorraine.fr/hal-02880287Test
https://hal.univ-lorraine.fr/hal-02880287/documentTest
https://hal.univ-lorraine.fr/hal-02880287/file/CKJ_Girerd_2020.pdfTest

المؤلفون: Girerd, Sophie, Girerd, Nicolas, Frimat, Luc, Holdaas, Hallvard, Jardine, Alan, Schmieder, Roland, Fellström, Bengt, Settembre, Nicla, Malikov, Sergei, Rossignol, Patrick, Zannad, Faiez

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Medical Department, Rikshospitalet, University of Oslo, Renal Research Group, British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), University of Glasgow-NHS Greater Glasgow and Clyde, Department of Nephrology and Hypertension, University Hospital Erlangen, Department of Nephrology, University Hospital, Uppsala, Service de Chirurgie Cardio-vasculaire CHRU Nancy, P.R., N.G. and F.Z. are supported by a public grant overseen by the French National Research Agency (ANR) as part of the second Investissements d’Avenir’ programme (reference ANR-15-RHU-0004). The subjects have given their written informed consent. The study protocol has been approved by the research institute’s committee on human research., ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: arteriovenous graft, chronic haemodialysis, cardiovascular mortality, arteriovenous fistula, vascular access complication, survival, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.Methods: The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome.Results: During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001].Conclusions: AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32082562; hal-02571720; https://hal.univ-lorraine.fr/hal-02571720Test; https://hal.univ-lorraine.fr/hal-02571720/documentTest; https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest; PUBMED: 32082562; PUBMEDCENTRAL: PMC7025348

الإتاحة: https://doi.org/10.1093/ckj/sfz048Test
https://hal.univ-lorraine.fr/hal-02571720Test
https://hal.univ-lorraine.fr/hal-02571720/documentTest
https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest

المؤلفون: Girerd, Sophie, Girerd, Nicolas, Frimat, Luc, Holdaas, Hallvard, Jardine, Alan, G, Schmieder, Roland, E, Fellström, Bengt, Settembre, Nicla, Malikov, Sergei, Rossignol, Patrick, Zannad, Faiez

المساهمون: Service de Néphrologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), University of Oslo (UiO), Renal Research Group, British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), University of Glasgow-NHS Greater Glasgow & Clyde Glasgow (NHSGGC), Department of Nephrology and Hypertension, University Hospital Erlangen, Uppsala University Hospital, Service de Chirurgie Cardio-vasculaire CHRU Nancy, P.R., N.G. and F.Z. are supported by a public grant overseen by the French National Research Agency (ANR) as part of the second Investissements d’Avenir’ programme (reference ANR-15-RHU-0004). The subjects have given their written informed consent. The study protocol has been approved by the research institute’s committee on human research., ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015)

المصدر: ISSN: 2048-8505.

مصطلحات موضوعية: survival, vascular access complication, chronic haemodialysis, cardiovascular mortality, arteriovenous fistula, arteriovenous graft, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.Methods: The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome.Results: During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001].Conclusions: AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32082562; hal-02571720; https://hal.univ-lorraine.fr/hal-02571720Test; https://hal.univ-lorraine.fr/hal-02571720/documentTest; https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest; PUBMED: 32082562; PUBMEDCENTRAL: PMC7025348

الإتاحة: https://doi.org/10.1093/ckj/sfz048Test
https://hal.univ-lorraine.fr/hal-02571720Test
https://hal.univ-lorraine.fr/hal-02571720/documentTest
https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdfTest